LEADING THE WAY IN ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT

Over the past several decades, Taiho has had a successful track record of producing anti-cancer treatments. These successes have brought us to where we are today, with a strong vision to lead the charge in combining conventional and targeted agents. Our unique two-pronged approach of continuously leveraging expertise in anti-metabolite therapies while also combining them with molecular targeted agents, has uncovered a wide range of potentially promising treatments for the future.

The content listed here is representative of US-based studies. For a full listing of all Taiho studies globally, please see the following:

Taiho Pharmaceutical Company

Preclinical
Phase 1
Phase 2
Phase 3
Filed

COMPOUND/MOA	COMPOUND/MOA	INDICATION
¹FUTIBATINIB Fibroblast growth factor receptor (FGFR) 1-4 inhibitor	Cholangiocarcinoma that has progressed after at least one prior line of systemic therapy	FILED
¹FUTIBATINIB Fibroblast growth factor receptor (FGFR) 1-4 inhibitor	Urothelial Cancer in Combination With Pembrolizumab	Phase 2
¹FUTIBATINIB Fibroblast growth factor receptor (FGFR) 1-4 inhibitor	Solid Tumors in combination with pembrolizumab	Phase 2
Zipalertinib Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations	Non-Small Cell Lung Cancer 1L	Phase 3
Zipalertinib Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations	Non-Small Cell Lung Cancer 2L+	Phase 2
²ASTX727 Decitabine and Cedazuridine Oral DNMT inhibitor	Hematological Malignancies	Phase 3
TAS0612 Small molecule triple kinase inhibitor of RSK1,2,3,4, AKT1,2,3 and S6K1,2	Solid Tumours	Phase 1
TAS2940 Covalent pan-ERBB inhibitor with high potency against HER2/EGFR exon20 insertion	Solid Tumours	Phase 1
TAS3351 4th Generation EGFR-TKI	Non-Small Cell Lung Cancer	Phase 1
ASTX030 Azacitidine and Cedazuridine Oral DNMT inhibitor	Hematological Malignancies	Phase 1

All data is current as of April 1, 2024.

* This material contains information regarding investigational agents that, unless otherwise indicated have not been approved for commercial use by any country's Regulatory Authority. The efficacy and safety for these investigational agents has not been established. There is no guarantee that these compounds will become commercially available or proven safe and effective for any particular therapeutic indication.

¹Futibatinib is approved in the following countries/regions: US, EU, UK, Japan. Please see local labeling for more information.

² Decitabine/cedazuridine is approved in the following countries/regions: US, Canada, Australia, EU, UK. Please see local labeling for more information.